VARIVAX II DIN 02240776
Status: Cancelled Post Market
Holder: MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.
Health Canada record
| Active ingredient(s) | VARICELLA-ZOSTER VIRUS VACCINE LIVE ATTENUATED (OKA/MERCK STRAIN) 1350 UNIT |
|---|---|
| Dosage form | Powder For Solution |
| Route | Subcutaneous |
| Schedule | SCHEDULE D |
| Class | Human |
| ATC | J07BK01 VARICELLA, LIVE ATTENUATED |
| Original market date | 27-Jun-2000 |
| Current status date | 27-Aug-2004 |
| Source | Health Canada DPD |
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing VARICELLA-ZOSTER VIRUS VACCINE LIVE ATTENUATED (OKA/MERCK STRAIN)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02239199 | VARIVAX | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | Powder For Solution | VARICELLA-ZOSTER VIRUS VACCINE LIVE ATTENUATED (OKA/MERCK STRAIN) 1350 UNIT | Cancelled Post Market |
| 02315939 | ZOSTAVAX | MERCK CANADA INC | Powder For Suspension | VARICELLA-ZOSTER VIRUS VACCINE LIVE ATTENUATED (OKA/MERCK STRAIN) 19400 PFU | Cancelled Post Market |
| 02375516 | ZOSTAVAX II | MERCK CANADA INC | Powder For Suspension | VARICELLA-ZOSTER VIRUS VACCINE LIVE ATTENUATED (OKA/MERCK STRAIN) 19400 PFU | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 1975 | 1999-08-26 | Supplement to a New Drug Submission (SNDS) | NEW STORAGE CONDITIONS; PRODUCT NAME CHANGE; COMPANY NAME CHANGE |